Sublingual Immunotherapy Effectiveness: The Clinical Evidence
Sublingual immunotherapy (SLIT) effectiveness is supported by 60+ randomized controlled trials. A Cochrane review of 60 trials found a standardized mean difference of -0.49 for symptoms and -0.32 for rescue medication versus placebo, and a JAMA 2013 review of 63 trials confirmed it reduces symptoms. Effect sizes are real and reproducible but not definitive. SLIT drops are off-label and not FDA-approved, and individual results vary.
5 peer-reviewed sources
Sublingual immunotherapy is effective and supported by 60+ randomized controlled trials. A Cochrane review found a symptom standardized mean difference of -0.49 versus placebo, a real, reproducible effect that varies by individual and cannot be guaranteed.
Key facts
A 2010 Cochrane review of 60 trials in 4,589 participants found a standardized mean difference of -0.49 for symptom scores and -0.32 for rescue medication use versus placebo, both statistically significant.
An effect size around -0.5 is conventionally read as a moderate, clinically relevant magnitude rather than a complete or definitive effect.
The 2013 JAMA review of 63 randomized trials graded the overall evidence as moderate, with 9 of 36 symptom studies showing greater than 40% improvement.
Allergy drops are compounded at a specialty pharmacy for each patient. The FDA does not review compounded products for safety or efficacy. Their evidence base is meaningful but less standardized than the approved tablets.
A 2026 real-world study of 2,897 patients found clinically meaningful improvement climbing from 28% at 12 months to 45% at 24 months on sublingual immunotherapy, with quality-of-life scores improving from 81% to 91% over time.
Effectiveness in Clinical Terms
Sublingual immunotherapy, abbreviated SLIT and known informally as allergy drops, is the practice of placing allergen extract under the tongue daily to gradually build immune tolerance. Asking about its effectiveness in clinical terms means looking past anecdotes to the measured effect across controlled trials, expressed in the language researchers actually use: effect sizes, comparisons against placebo, and evidence grading.
The most rigorous summary comes from systematic reviews and meta-analyses. A Cochrane review (Radulovic et al., 2010) pooling 60 randomized controlled trials in 4,589 participants found a standardized mean difference of -0.49 for symptom scores and -0.32 for rescue medication use versus placebo, both statistically significant. A negative standardized mean difference here means SLIT-treated patients had lower symptom and medication burdens than placebo, and an effect around -0.5 is generally considered a moderate, clinically relevant magnitude. The JAMA 2013 review (Lin et al.) of 63 trials independently graded the overall evidence as moderate.
Because effectiveness depends on treating the correct triggers, accurate diagnosis comes first. Curex starts with at-home allergy testing reviewed by a licensed allergist to confirm your specific IgE sensitizations before any immunotherapy plan is built.
In clinical terms, SLIT shows a reproducible effect over placebo, supported by 60+ randomized controlled trials including Cochrane effect sizes and a JAMA 2013 review, meaningful but not a guarantee.
The Immunology Behind the Effect Sizes
The Cochrane effect sizes do not appear from nowhere; they are the measurable footprint of a specific immunological process. Sublingual immunotherapy exploits the tolerogenic environment of the oral mucosa, where specialized dendritic cells sample antigen and tend to promote regulation rather than inflammation. Sustained daily exposure drives a coordinated shift, more regulatory T cells, a rise in protective IgG4 blocking antibodies, and dampened Th2 signaling, that collectively reduce the allergic reaction on natural exposure. The standardized mean difference of -0.49 for symptoms is, in essence, this biological shift expressed as a number.
Mucosal Antigen Sampling
Oral Langerhans and dendritic cells take up the sublingual allergen and, in this tolerance-prone tissue, tend to present it in a way that calms rather than escalates the immune response.
Regulatory and Antibody Shift
Allergen-specific regulatory T cells expand and IgG4 blocking antibodies rise, intercepting allergen before it can cross-link IgE on mast cells and basophils.
Reduced Clinical Reaction
Less mediator release on exposure shows up in trials as lower symptom and rescue-medication scores, the very outcomes summarized by the Cochrane effect sizes.
Ready to skip the needles?
See if at-home allergy drops fit your allergies โ a 2-minute quiz, designed by board-certified allergists, taken under the tongue daily with no clinic visits.
- AllergistReviewed & prescribed
- Quote requiredConfirm program pricing
- No needlesUnder the tongue
- HSA/FSAEligible
See how Curex's allergist-guided drops program compares for your allergies.
See if you qualify for Curex's at-home allergy drops program, with testing and care guided by a licensed allergist.
Allergy drops are compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
See if you qualifyFrequently asked questions
What does a standardized mean difference of -0.49 mean for SLIT?
A standardized mean difference, or SMD, expresses the gap between two groups in standard-deviation units, allowing results from different trials and scales to be combined. The Cochrane review of 60 sublingual immunotherapy trials found an SMD of -0.49 for symptom scores versus placebo, where the negative sign means SLIT-treated patients had fewer symptoms than placebo patients. An SMD around -0.5 is conventionally interpreted as a moderate effect: meaningful and clinically relevant, with the groups still overlapping rather than being completely separated. In plain language, the average person on SLIT did noticeably better than the average person on placebo. It is solid evidence of benefit, not proof that every individual will respond.
Is sublingual immunotherapy as effective as subcutaneous immunotherapy?
Both are effective, and comparing them requires nuance. Subcutaneous immunotherapy (allergy shots) has a long, standardized evidence record, while sublingual immunotherapy has moderate-grade evidence from many trials, including the Cochrane analysis showing a significant effect versus placebo. Some head-to-head and indirect comparisons suggest shots may carry a modest edge for certain allergens, but results are not uniform, and confidence intervals often overlap. Rather than a blanket ranking, the responsible statement is that sublingual immunotherapy carries a lower risk of systemic reactions while subcutaneous has deeper evidence for some allergens. The most effective option for a given person depends on their allergens and is best decided with a licensed allergist.
Why is the evidence graded moderate rather than high?
Evidence grading considers consistency, study quality, and how directly trials measure outcomes. Sublingual immunotherapy earns a moderate grade because many randomized trials point the same direction, confirming a real benefit, but they vary in allergen, dose, treatment duration, and how they define and measure response. That heterogeneity introduces some uncertainty, which keeps the grade below the highest tier reserved for very large, uniform, low-bias evidence. Moderate grade is genuinely reassuring; it means the effect is reproducible and unlikely to be chance. It also signals appropriate caution: effectiveness varies between individuals, and outcomes cannot be guaranteed, so claims should be hedged rather than absolute.
Does SLIT effectiveness differ for tablets versus liquid drops?
The evidence differs in standardization. FDA-approved SLIT tablets, such as Grastek, Oralair, Ragwitek, and Odactra, went through dedicated trials for single allergens and carry well-characterized effectiveness data. Custom liquid drops are compounded for individualized, often multi-allergen treatment and are used off-label in the United States; their evidence base is meaningful but less standardized than the approved tablets. Both work through the same sublingual mechanism. The practical implication is that effectiveness expectations should be framed honestly: tablets have tightly defined trial data for specific allergens, while drops offer personalization supported by the broader moderate-grade SLIT literature. A licensed allergist can explain which approach best fits your particular sensitizations.
How much symptom improvement can SLIT realistically deliver?
Realistic expectations center on meaningful reduction rather than elimination. The Cochrane symptom effect size of -0.49 versus placebo and the JAMA finding that 9 of 36 studies showed greater than 40% improvement both point to substantial but partial relief for many patients. Practically, that often looks like milder symptoms, fewer bad days during peak season, and less need for rescue antihistamines, built up over a multi-year course. It does not typically mean becoming completely allergy-free. Because effectiveness varies with allergen, dose, and adherence, your own result may fall anywhere along that range. Setting the goal as significant, lasting improvement gives a more accurate picture than expecting symptoms to disappear entirely.
Does sublingual immunotherapy effectiveness differ for asthma versus rhinitis?
The strongest and most consistent effectiveness evidence is for allergic rhinitis and rhinoconjunctivitis, which is the primary focus of the JAMA 2013 review and the Cochrane analysis. Sublingual immunotherapy has also been studied for allergic asthma, and the JAMA review examined asthma outcomes alongside rhinitis, finding supportive but somewhat less consistent evidence there. In practice, many patients have both conditions driven by the same allergens, so treatment can help on both fronts. However, immunotherapy is not a standalone asthma treatment, and uncontrolled or severe asthma is actually a contraindication that must be addressed first for safety. The honest summary is that effectiveness is best established for allergic nasal and eye symptoms, with a supportive but more nuanced role in allergic asthma that a specialist should guide.
Is Curex FDA-approved?
Curex's at-home SCIT (allergy shots) and compounded allergy treatment are not FDA-approved drug products in themselves. They are individually compounded, a different regulatory category from an approved drug. Separately, FDA-approved tablets โ Grastek, Oralair, Ragwitek, and Odactra โ exist for specific single allergens and are sold apart from compounded drops or custom serums. Compounding is overseen under USP <797> sterile standards, and the allergen extracts come from FDA-licensed manufacturers. Ask your allergist whether an FDA-approved tablet or a compounded, personalized treatment fits your situation.
How does Curex compare to Wyndly?
Both are legitimate options that deliver the same core treatment and can get patients real relief โ they're just structured differently. Wyndly is a premium, streamlined program built on ENT protocols for environmental allergies, using an at-home finger-prick test, an in-depth video visit to start, and ongoing text check-ins; it's self-pay, and most patients choose the annual plan, around $1,200 per year. Curex uses allergist protocols with ImmunoCAP testing (done at a lab or at home), covers both environmental and food allergies, holds regular video visits, and accepts insurance, with plans starting from $39 per month. The right fit depends on whether you want a self-pay streamlined program or an insurance-accepted, broader-scope option.
How does Curex compare to Quello?
Quello is one of several newer telehealth options in the allergy-treatment space, and specifics like pricing, testing method, and insurance acceptance can change, so it's worth checking Quello's current offering directly rather than relying on a comparison here. What's established about Curex: testing is confirmed through ImmunoCAP (lab or at-home), treatment follows standard allergist-directed protocols for SCIT or SLIT, insurance is accepted, and plans start from $39 per month. When comparing any two allergy-treatment companies, the practical things to check are: which testing method is used, whether the clinical protocol matches standard allergist practice, whether insurance is accepted, and what ongoing clinician support looks like during treatment.
How is Curex different from at-home allergy test companies like imaware, Everlywell, or LetsGetChecked?
Those companies primarily sell at-home blood tests that measure IgE antibody levels for common allergens and return results directly to you. Curex includes testing as one part of a full treatment pathway: a licensed allergist reviews your results over telehealth and, if appropriate, prescribes a personalized immunotherapy program (allergy shots or drops) built around what you're actually sensitized to, with ongoing clinical support through treatment. If you only want a test result and no treatment plan, a standalone test kit may be sufficient; if you want testing that leads directly into allergist-guided treatment, that's the gap Curex is built to fill.
What is the success rate of sublingual immunotherapy?
There's no single 'success rate' number, because trials measure improvement in symptom scores and medication use rather than a pass/fail outcome, and results vary by allergen, dose, and how long someone stays on treatment. The clearest summary from the available evidence: a Cochrane review of 60 trials found a moderate, statistically significant symptom improvement versus placebo, and a JAMA review found that 9 of 36 studies showed more than 40% symptom improvement. That translates to most patients experiencing real, meaningful relief rather than full symptom elimination, with individual results varying.
Related Articles
How Many Drops in Sublingual Immunotherapy?
How many drops in sublingual immunotherapy? The count varies by protocol, concentration, and provider. Learn how your drop dose is set.
Read moreWhat Is Sublingual Immunotherapy? A Clinical Definition
Sublingual immunotherapy (SLIT) is allergy treatment taken under the tongue as drops or tablets to build tolerance to allergens. See the definition.
Read moreSublingual Immunotherapy (Allergy Drops): How It Works, Evidence and Cost
Sublingual immunotherapy (SLIT) explained: how allergy drops and tablets work, evidence vs allergy shots, safety, timeline, and cost from $39/month.
Read moreSublingual Allergy Drops: What Sublingual Really Means
Sublingual allergy drops go under the tongue, not in your eyes. Learn what sublingual means, how the route works, and how drops differ from eye drops.
Read moreHow Do Allergy Drops Work? The Immunology of SLIT
How do allergy drops work? Under the tongue, immune cells sample the allergen and shift the body toward tolerance via Treg cells and IgG4 antibodies.
Read moreAre Allergy Drops Effective? Understanding the Evidence Quality
Are allergy drops effective? Yes, backed by 60+ randomized controlled trials. We explain what the evidence shows and why it matters more than one number.
Read moreQuestions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs.
Treat your allergies โ drops under the tongue.
Curex allergy drops are a personalized sublingual extract, prescribed by a board-certified allergist and shipped to your door โ taken daily at home with no needles and no routine clinic visits. Confirm your current treatment quote. HSA/FSA eligible.
Confirm your quote ยท Remaining payments for shipped treatment are collected on cancellation
Allergy drops are compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Allergy drops are compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
The only FDA-approved sublingual immunotherapy products are tablets โ Grastek, Oralair, Ragwitek, and Odactra โ which are different from Curex drops.